Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | PRNP | P04156 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaminophen SCHEMBL2128715 | 0.91 | MAPT (0.71) | SMN1; SMN2HTTL3MBTL1TSHRHDAC3 | |
| Acetaminophen SCHEMBL1649625 | 0.89 | MAPT (0.69) | SMN1; SMN2HTTL3MBTL1TSHRHDAC3 | |
| SCHEMBL48610 | 0.87 | TSHR (0.69) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E | |
| SCHEMBL3818831 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E | |
| Pyridine SCHEMBL27521497 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTL3MBTL1TSHRHDAC1 | |
| Water SCHEMBL11515613 | 0.85 | TSHR (0.67) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL11146958 | 0.85 | TSHR (0.67) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E | |
| Acetic Acid SCHEMBL9762020 | 0.83 | TSHR (0.65) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E | |
| SCHEMBL4516268 | 0.82 | ROCK2 (0.57) | SMN1; SMN2HTTL3MBTL1HDAC1KDM4E | |
| SCHEMBL9762638 | 0.81 | SMN1; SMN2 (0.86) | SMN1; SMN2HTTL3MBTL1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023280294-A1 | TARGET AND SMALL MOLECULE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES OR CENTRAL NERVOUS SYSTEM INJURY | 北京干细胞与再生医学研究院 | 2023-01-12 | — | — | WO | disclosed |
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| CN-105517993-B | Aryl amide kinase inhibitors | 百时美施贵宝公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-106061974-B | Maleimide derivatives as the conditioning agent of WNT approach | 新加坡科技研究局 | 2018-04-20 | — | — | CN | disclosed |
| WO-2017008708-A1 | METHOD FOR PREPARING INDAZOLE COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2017-01-19 | — | — | WO | disclosed |
| CN-106317023-A | Preparation method and application of indazole compound | 中国科学院上海药物研究所 | 2017-01-11 | — | — | CN | disclosed |
| CN-106061974-A | Maleimide derivatives as modulators of WNT pathway | 新加坡科技研究局 | 2016-10-26 | — | — | CN | disclosed |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-4377585-A | Use of 4-[4(or 3)-aminophenyl]pyridines as cardiotonic agents | STERLING DRUG INC. (US) | 1983-03-22 | — | — | US | disclosed |
| EP-0056260-A1 | Pyridinyl-substituted-benz imidazole derivatives and preparation | STERLING DRUG INC. (US) | 1982-07-21 | — | — | EP | disclosed |
| US-4331671-A | 5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use | STERLING DRUG INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4317827-A | 4-[4(or 3)-Acylaminophenyl]pyridines and their use as cardiotonics | STERLING DRUG INC. (US) | 1982-03-02 | — | — | US | disclosed |
| US-3994903-A | Preparation of 4-(3-nitrophenyl)pyridine | STERLING DRUG INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | SMN1; SMN2 3740/4885HTT 4288/4885L3MBTL1 2143/4885 |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | SMN1; SMN2 3607/4885HTT 3593/4885L3MBTL1 3299/4885 |
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | SMN1; SMN2 3740/4885HTT 4288/4885L3MBTL1 2143/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | SMN1; SMN2 976/4885HTT 1570/4885L3MBTL1 1268/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | SMN1; SMN2 2790/4885HTT 3260/4885L3MBTL1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.